SMS Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de SMS Pharmaceuticals' es Ramesh Potluri , nombrado en Aug 1990, tiene una permanencia de 34.08 años. compensación anual total es ₹30.75M, compuesta por 97.6% salario y 2.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 36.22% de las acciones de la empresa, por valor de ₹10.39B. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 2.2 años, respectivamente.
Información clave
Ramesh Potluri
Chief Executive Officer (CEO)
₹36.9m
Compensación total
| Porcentaje del salario del CEO | 81.4% |
| Permanencia del CEO | 34.1yrs |
| Participación del CEO | 36.2% |
| Permanencia media de la dirección | 5.3yrs |
| Promedio de permanencia en la Junta Directiva | 2.2yrs |
Actualizaciones recientes de la dirección
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹570m |
| Mar 31 2024 | ₹37m | ₹30m | ₹498m |
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
Compensación vs. Mercado: La compensación total de Ramesh($USD368.51K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD186.19K).
Compensación vs. Ingresos: La compensación de Ramesh ha sido consistente con los resultados de la empresa en el último año.
CEO
Ramesh Potluri (66 yo)
34.1yrs
Permanencia
₹36,875,000
Compensación
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & MD | 34.1yrs | ₹36.88m | 36.22% ₹ 10.8b | |
| Chief Financial Officer | 7yrs | ₹2.37m | sin datos | |
| Company Secretary & Compliance Officer | 2.6yrs | ₹1.53m | sin datos | |
| Executive Director | 3.7yrs | ₹36.83m | 15.74% ₹ 4.7b | |
| Assistant General Manager of HR and Legal | no data | sin datos | sin datos | |
| Head of HRD and General Manager of Purchases | no data | sin datos | sin datos |
5.3yrs
Permanencia media
61yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SMSPHARMA es experimentado (5.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & MD | 34.1yrs | ₹36.88m | 36.22% ₹ 10.8b | |
| Executive Director | 4.3yrs | ₹36.83m | 15.74% ₹ 4.7b | |
| Additional Non-Executive Non-Independent Director | less than a year | sin datos | 2.58% ₹ 768.4m | |
| Non-Executive & Independent Director | 5.1yrs | ₹245.00k | sin datos | |
| Non-Executive & Independent Director | 6.3yrs | ₹590.00k | 0.035% ₹ 10.5m | |
| Additional Non-Executive Independent Director | less than a year | sin datos | sin datos | |
| Non-Executive Non-Independent Director | less than a year | sin datos | sin datos | |
| Non-Executive Independent Director | less than a year | sin datos | sin datos |
2.2yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de SMSPHARMA no se considera experimentada (2.1 años de permanencia promedio), lo que sugiere una nueva junta directiva.